Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02472301
Other study ID # LG2
Secondary ID
Status Completed
Phase N/A
First received June 9, 2015
Last updated May 10, 2017
Start date August 2015
Est. completion date December 2016

Study information

Verified date May 2017
Source Washington University School of Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To determine if 12 months of legume-based complementary foods is effective in reducing or reversing EED and linear growth faltering in a cohort of Malawian children, aged 12-35 months to see if these improvements are correlated with specific changes in the enteric microbiome.


Recruitment information / eligibility

Status Completed
Enrollment 337
Est. completion date December 2016
Est. primary completion date December 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 12 Months to 35 Months
Eligibility Inclusion Criteria:

- children residing in catchment area of Limela, Machinga District and N tenda (Chikwawa District), Malawi

- aged 12-35 months

- youngest eligible child in each household

Exclusion Criteria:Unable to drink 20 mL of sugar water

- Demonstrating evidence of severe acute malnutrition, WHZ < or = -3, presence of bi-pedal pitting edema

- Apparent need for acute medical treatment for an illness or injury

- Caregiver refusal to participate and return for 3, 6 and 12 month follow-ups

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
cowpeas complementary food
cowpeas supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
corn-soy flour
Corn-soy flour supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
common bean complementary food
common bean supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Washington University School of Medicine

Country where clinical trial is conducted

Malawi, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dual Sugar Absorption Test lactulose-mannitol ratio in urine 3 months
Primary Dual Sugar Absorption Test lactulose-mannitol ratio in urine 6 months
Primary Dual Sugar Absorption Test lactulose-mannitol ratio in urine 12 months
Secondary Lactulose Excretion percentage of ingested lactulose excreted in urine 3 months
Secondary Lactulose Excretion percentage of ingested lactulose excreted in urine 6 months
Secondary Lactulose Excretion percentage of ingested lactulose excreted in urine 12 months
Secondary Mannitol Excretion percentage of ingested mannitol excreted in urine 3 months
Secondary Mannitol Excretion percentage of ingested mannitol excreted in urine 6 months
Secondary Mannitol Excretion percentage of ingested mannitol excreted in urine 12 months
See also
  Status Clinical Trial Phase
Completed NCT02253095 - Combined Package of Interventions for Environmental Enteropathy N/A
Completed NCT01832636 - Intervention and Mechanisms of Alanyl-Glutamine for Inflammation, Nutrition, and Enteropathy Phase 3
Active, not recruiting NCT04565821 - Feasibility Study to Assess a Trans-nasal Intestinal Potential Difference Probe N/A
Completed NCT01593033 - Effectiveness of Micronutrient Supplementation and Fish Oil + Micronutrient Supplementation in the Treatment of Environmental Enteropathy N/A
Active, not recruiting NCT03713502 - Enteropathy and Diabetes in HIV Patients
Not yet recruiting NCT05608928 - Ability of the Probiotic Vivomixx to Improve Environmental Enteropathy in Pregnant Women: a Proof of Concept Trial in Bangladesh, Pakistan, Senegal and Zambia Phase 2